^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Serine protease inhibitor

5d
Effects of Red and Infrared Photobiomodulation in Rhinoplasty at a Single Centre (clinicaltrials.gov)
P=N/A, N=60, Recruiting, University of Nove de Julho | Not yet recruiting --> Recruiting | Trial completion date: Jul 2030 --> Nov 2030 | Initiation date: Oct 2025 --> Jan 2026
Enrollment open • Trial completion date • Trial initiation date
16d
Comparison of Anticoagulant Effects Between Nafamostat Mesylate and Sodium Citrate in Double Filtration Plasmapheresis (ChiCTR2600117445)
P=N/A, N=140, Not yet recruiting, The First Affiliated Hospital of Army Medical University PLA; The First Affiliated Hospital of Army Medical University PLA
New trial
|
nafamostat
16d
A Randomized, Active-Controlled, Open-Label Clinical Study of Nafamostat Mesylate for Reducing Bleeding Risk in Maintenance Hemodialysis Patients at High Risk of Bleeding (ChiCTR2600116304)
P=N/A, N=338, Not yet recruiting, The Seventh Affiliated Hospital Sun Yat-sen University; The Seventh Affiliated Hospital of Sun Yat-sen University
New trial
|
nafamostat • enoxaparin sodium
19d
HSP90α and KLK6 Coregulate Stress-Induced Prostate Cancer Cell Motility. (PubMed, Cells)
Screening for protease inhibitors that would rescue stress-induced decreases in MMP-2 activity identified a single serine protease inhibitor: aprotinin...In conclusion, we identify a novel stress-induced extracellular network that regulates MMP-2 activity and cell motility. We identified KLK6 as a stress-induced extracellular protease leading to decreased MMP-2 activity and cellular invasion, while eHSP90α is required for the rescue of MMP-2 activity once KLK6 is neutralized.
Journal
|
MMP2 (Matrix metallopeptidase 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • KLK6 (Kallikrein Related Peptidase 6)
20d
Exploring Molecular Signature and Prognostic Biomarkers in Ovarian Cancer: Insights From Late-Stage, Recurrent, and Metastatic Tumors. (PubMed, Biotechnol Appl Biochem)
Ocriplasmin and pamidronate were identified as potential therapeutics. Our findings highlight the therapeutic relevance of these hub genes and identify them as potential drug targets and prognostic biomarkers in ovarian cancer.
Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • IGF1 (Insulin-like growth factor 1) • FN1 (Fibronectin 1) • COL1A1 (Collagen Type I Alpha 1 Chain) • COL3A1 (Collagen Type III Alpha 1 Chain) • MIR29A (MicroRNA 29a) • POSTN (Periostin)
|
pamidronate disodium
1m
Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery (clinicaltrials.gov)
P4, N=160, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting
Enrollment open
1m
Single Versus Multi-Dose Oral and Intravenous Tranexamic Acid Patients at High Risk for Blood Transfusion After Spine Surgery (clinicaltrials.gov)
P1, N=604, Recruiting, Rush University Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
1m
HSP90α and KLK6 Co-Regulate Stress-Induced Prostate Cancer Cell Motility. (PubMed, bioRxiv)
Screening for protease inhibitors that would rescue stress-induced decreases in MMP-2 activity identified a single serine protease inhibitor: aprotinin...We identify a novel stress-induced extracellular network that regulates MMP-2 activity and cell motility. We identified KLK6 as a stress-induced extracellular protease leading to decreased MMP-2 activity and cellular invasion, while eHSP90α is required for the rescue of MMP-2 activity once KLK6 is neutralized.
Journal
|
MMP2 (Matrix metallopeptidase 2) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1) • KLK6 (Kallikrein Related Peptidase 6)
2ms
Tranexamic Acid to Reduce Delirium After Gastrointestinal Surgery: the TRIGS-D Trial (clinicaltrials.gov)
P3, N=826, Active, not recruiting, Bayside Health | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Aug 2026 | Trial primary completion date: Dec 2025 --> Aug 2026
Enrollment closed • Trial completion date • Trial primary completion date
2ms
The Effect of Local and Systemic Tranexamic Acid on Edema and Ecchymosis in Orbital Surgery (clinicaltrials.gov)
P4, N=150, Recruiting, Montefiore Medical Center | Suspended --> Recruiting
Enrollment open